Cooperative Agreement D25AC00432
Award Date 9/25/25
Completion Date 9/24/28
Dollars Obligated $18M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
California, USA
Similar Awards
- Federal Cooperative Agreement Summary Award: Carnegie Mellon University received an $18.05 million Cooperative Agreement from the Advanced Research Projects Agency for Health (ARPA-H), CFDA 93.384, awarded September 26, 2025, with completion targeted for September 25, 2028. The funding supports the Liver Immunocompetent Volumetric Engineering (LIVE) initiative, which aims to develop 3D bioprinted liver tissue constructs to address the critical public health challenge of liver disease, which...
- Federal Cooperative Agreement Summary Award Details: Funding Agency: Advanced Research Projects Agency for Health (ARPA-H), National Institutes of Health Federal Grant Program: ARPA-H (CFDA 93.384) Prime Recipient: President and Fellows of Harvard College Award Amount: $17.815 million Award Date: September 26, 2025 Completion Date: September 25, 2028 Place of Performance: Massachusetts Scope of Work: Harvard College will develop the first off-the-shelf engineered liver tissue product to...
- Federal Cooperative Agreement Summary The University of Texas Southwestern Medical Center received a $14.33 million Cooperative Agreement awarded September 10, 2025, under the Advanced Research Projects Agency for Health (ARPA-H) program (CFDA 93.384) to develop a Vascularized Immunocompetent Tissue as an Alternative Liver (VITAL). The three-year project, concluding September 9, 2028, focuses on creating a functional bioengineered liver organ suitable for orthotopic transplantation. Technical...
- Wake Forest University Health Sciences received a $13.43 million Cooperative Agreement from the Advanced Research Projects Agency for Health (ARPA-H, CFDA 93.384) awarded September 26, 2025, with completion targeted for September 25, 2028. The award funds development of bioprinted vascularized autologous renal tissue constructs designed to augment renal function in patients with kidney disease. The institute will leverage its two decades of experience in three-dimensional (3D) printing...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Washington $839,388 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop engineered human liver tissue for heterotopic transplant and therapeutic rescue of liver disease. The project addresses the critical shortage of donor organs for patients with end-stage liver disease by developing cultured human hepatocytes as organoids that...
- The Regents of the University of California, San Francisco (UCSF) has been awarded a $31,110,405.00 Cooperative Agreement by the Department of the Interior's Interior Business Center under the Advanced Research Projects Agency for Health (ARPA-H) program (CFDA 93.384). This 5-year award, effective April 1, 2024, supports the development of a "Programmable Platform for Targeting Therapies to the Brain" to advance cell therapies for neuroinflammation and neurodegeneration. The ARPA-H...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $584,232 to Renovate Biosciences Inc. on September 25, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). Renovate Biosciences will generate human livers from donor patient-specific cells using pigs as bio-incubators. Following technical validation, the work will establish a pathway for producing on-demand transplantation-ready hepatocytes for cellular therapies and...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of Notre Dame $662,737 on March 5, 2026, to develop autonomous hybrid bioprinting technology for hierarchical perfusable vascularized liver tissues under NIH Discovery and Applied Research for Technological Innovations to Improve Human Health (CFDA 93.286). The project integrates aerosol jet sacrificial printing and extrusion bioprinting methods to construct three-dimensional complex vascular structures with...
- This federal Project Grant award of $460,500 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) is aimed at developing novel bioprinting methodologies for the production of human stem cell-based organoids. The key objectives are to: 1) Create a customized bioink formulation using proteins, polysaccharides, and functionalized nanoparticles to foster the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Regents of the University of California, San Francisco $626,188 on May 15, 2026, to develop a therapy for human cholestatic liver diseases based on hepatocyte plasticity. The research aims to investigate how hepatocyte plasticity—the ability of liver cells to assume a biliary identity and form functional bile ducts—can be harnessed therapeutically in diseases including Alagille Syndrome and primary sclerosing...